Navigation Links
Anesiva to Present at BioCentury Newsmakers Conference on September 4, 2008

SOUTH SAN FRANCISCO, Calif., Aug. 29 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that Michael L. Kranda, the company's president and chief executive officer, will present at BioCentury's Newsmakers in the Biotech Industry Conference in New York City on September 4, 2008 at 2:00 p.m. ET.

To access the live webcast or the subsequent archived recording, log on to, go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. For full Zingo prescribing information and other information, visit An sNDA is under review at FDA to expand the Zingo label indication to include adults.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in Phase 3 clinical trials for the management of acute pain following orthopedic surgeries. Adlea has been shown to reduce pain after only a single administration for up to weeks to months in multiple settings based on the results of several mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Announces Second Quarter 2008 Financial Results and Update
2. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
3. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
4. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
5. Anesiva Announces First Quarter 2008 Financial Results
6. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
7. Anesiva Announces Expansion of Zingo Agreement in Europe
8. Anesiva Announces New Zingo Marketing and Distribution Agreement
9. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
10. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... December 29, 2015 at 11:00 a.m. Israel time, ... Tower, 98 Yigal Allon Street, 36 th Floor, Tel ... Eric Paneth and Izhak Tamir to the Board ... Skaliter as external directors; , approval of an amendment to certain ...
Breaking Biology Technology:
(Date:10/26/2015)... NEWARK, Calif. , Oct. 26, 2015  Delta ... convenient biometric authentication to mobile and PC devices, announced ... Fujitsu,s smartphone, the arrows NX F-02H launched by NTT ... arrows NX F-02H is the second smartphone to include ... this technology in ARROWS NX F-04G in May 2015, ...
(Date:10/23/2015)... and GOLETA, California , October ... conference, BIOPAC and SensoMotoric Instruments (SMI) announce a mobile ... tracking data captured during interactive real-world tasks ... play integration of their established wearable solutions for eye ... synchronize gaze behavior captured with SMI Eye Tracking ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):